Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

The ASH Research Collaborative (ASH RC) will present new multiple myeloma and sickle cell disease data at the 66th ASH Annual ...

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

Jeff Friedman of FBVF. Additional significant support came from the Multiple Myeloma Research Foundation (MMRF), through its venture philanthropy arm, the Myeloma Investment Fund (MIF), underscoring ...

Bishop Kiuna passed away on July 9,2024 at a hospital in Nairobi after bravely battling Multiple Myeloma. 'When is the ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the ...

Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven ...

We’ve always had a very close relationship,” one twin said. “People always said we were like one coat of paint.” ...

The 66th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood ...

Researchers sought to determine whether PRD monitoring would be a suitable replacement for MRD in multiple myeloma.

Stephan Mertens passed away on October 9, 2024, at the age of 62 after a seven-year battle with multiple myeloma. At the time ...